One project will build on Marinova’s existing data of scientific evidence relating to fucoidans and healthy aging. The project includes investigations into a range of natural aging and accelerated aging processes. The project will also extend into studies exploring the potential protective roles of high purity fucoidans when administered alongside common chemotherapeutics.
The second project focuses on the chronic inflammatory respiratory disease eosinophilic oesophagitis (EoE). According to the company, despite the growing global prevalence of EoE, the diagnosis, treatment and management of the disease remain challenging. A human clinical trial will explore the effectiveness of high purity fucoidans to alleviate the symptoms of EoE.
The two research projects received grant funding from the Australian Government through the Marine Bioproducts Cooperative Research Centre (MB-CRC), a $270 million, decade-long R&D program.
“Marinova is proud to be a part of this innovative Australian consortium of industry, government and academic partners,” said Paul Garrott, Marinova's CEO and managing director. “We are delighted that the program can fast-track several very significant research projects that we have planned for our fucoidan extracts."